BBP-418

Phase 3Small molecule

MML Bio Solutions, Inc.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Limb-Girdle Muscular Dystrophy Type 2i (LGMD2I)Active, not recruiting

LGMD2IActive, not recruiting

Limb-Girdle Muscular Dystrophy Type 2i (LGMD2I)Phase 3

Active, not recruiting

LGMD2IPhase 2

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

LGMD2I

NCT04800874

Q3 2027

Phase 3Active, not recruiting

Limb-Girdle Muscular Dystrophy Type 2i (LGMD2I)

NCT05775848

Q4 2030

Phase 3Active, not recruiting

Limb-Girdle Muscular Dystrophy Type 2i (LGMD2I)

NCT07678775

Clinical

Trials by Indication[1]

Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)2 trials

A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Active, not recruiting·MML Bio Solutions, Inc.·Phase 3·NCT05775848·112 enrolled

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants With Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)

Active, not recruiting·MML Bio Solutions, Inc.·Phase 3·NCT07678775·107 enrolled

LGMD2I1 trial

An Open Label Phase 2 Study of BBP-418 in Patients With Limb Girdle Muscular Dystrophy Type 2I (MLB-01-003)

Active, not recruiting·MML Bio Solutions, Inc.·Phase 2·NCT04800874·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BBP-418. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BBP-418 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BBP-418. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ML Bio Solutions, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MML Bio Solutions, Inc.